Literature DB >> 21969848

Focal therapy for prostate cancer - where are we in 2011?

Michael S Borofsky1, Timothy Ito, Andrew B Rosenkrantz, Samir S Taneja.   

Abstract

Prostate cancer treatment is a controversial topic amongst physicians and patients alike. Radical therapies such as prostatectomy and whole gland radiation offer the best outcomes in terms of oncologic efficacy, but the decision to undergo treatment must be weighed against its potential morbidity. Over the past decade, the concept of focal therapy for prostate cancer has been introduced as a potential method of achieving oncologic control with a lesser degree of morbidity. Focal therapy refers to isolated ablation of a tumor focus with sparing of uninvolved, surrounding tissue. While it remains in the early stages of development, considerable research is underway that will help determine the optimal method of achieving this goal. Current areas of investigation include appropriate candidate selection, lesion identification, modality of treatment, and follow-up strategies.

Entities:  

Keywords:  cryotherapy; focal therapy; high-intensity focused ultrasound (HIFU); histoscan; prostate cancer

Year:  2011        PMID: 21969848      PMCID: PMC3175702          DOI: 10.1177/1756287211418724

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  57 in total

Review 1.  Photodynamic therapy for focal ablation of the prostate.

Authors:  Nimalan Arumainayagam; C M Moore; Hashim U Ahmed; M Emberton
Journal:  World J Urol       Date:  2010-05-09       Impact factor: 4.226

2.  Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.

Authors:  F Parivar; H Hricak; K Shinohara; J Kurhanewicz; D B Vigneron; S J Nelson; P R Carroll
Journal:  Urology       Date:  1996-10       Impact factor: 2.649

3.  The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer.

Authors:  Simon R J Bott; Hashim U Ahmed; Richard G Hindley; Ahmad Abdul-Rahman; Alex Freeman; Mark Emberton
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

4.  Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.

Authors:  E T Ruijter; C A van de Kaa; J A Schalken; F M Debruyne; D J Ruiter
Journal:  J Pathol       Date:  1996-11       Impact factor: 7.996

5.  Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.

Authors:  Philippe Puech; Eric Potiron; Laurent Lemaitre; Xavier Leroy; Georges-Pascal Haber; Sebastien Crouzet; Kazumi Kamoi; Arnauld Villers
Journal:  Urology       Date:  2009-09-20       Impact factor: 2.649

6.  Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables.

Authors:  H Augustin; G A Fritz; T Ehammer; M Auprich; K Pummer
Journal:  Acta Radiol       Date:  2009-06       Impact factor: 1.990

7.  Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort.

Authors:  Basir Tareen; Alex Sankin; Guilherme Godoy; Steve Temkin; Herbert Lepor; Samir S Taneja
Journal:  Urology       Date:  2008-11-26       Impact factor: 2.649

8.  Image guided photothermal focal therapy for localized prostate cancer: phase I trial.

Authors:  U Lindner; R A Weersink; M A Haider; M R Gertner; S R H Davidson; M Atri; B C Wilson; A Fenster; J Trachtenberg
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

9.  Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results.

Authors:  David S Ellis; Theodore B Manny; John C Rewcastle
Journal:  Urology       Date:  2007-12       Impact factor: 2.649

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.